Home » Newsletters » BioWorld Science

BioWorld Science

April 9, 2009

View Archived Issues

Screening study shows reduced prostate cancer risk with finasteride across PSA levels

Novel series of hypoxia-activated compounds identified by Threshold Pharmaceuticals

Array BioPharma patent claims new tyrosine kinase inhibitors for cancer treatment

Schering-Plough patent discloses novel gamma-secretase modulators for the treatment of AD

New compounds for the treatment of hepatitis C claimed in Schering-Plough patents

New liver X receptor ligands under study at Organon for atherosclerosis

New myocardial imaging tracer shows safety and good biodistribution profile in phase I trial

Novel inhibitors of Abeta calcium channel activity confer neuroprotection in vitro

Alkermes advances proprietary pipeline

Avineuro commences phase I AVN-101 study for Alzheimer's disease

Cancer Therapy & Research Center and OncoVista collaborate on OVI-117

Somaxon provides update on NDA for Silenor for insomnia

GLYC-101 achieves accelerated wound closure based on interim analysis

Gen-Probe acquires Tepnel Life Sciences

BioWa licenses Potelligent Technology to sanofi-aventis

Cordex Pharma and BG Medicine collaborate on phase II trial of CDP-1050

Array BioPharma initiates clinical trial for ARRY-403 in type 2 diabetes

Amarin's MAA for AMR-101 in Huntington's disease accepted for review

IntelGenx and Cary file NDA for antidepressant, CPI-300

Cetuximab with chemotherapy as first-line treatment for metastatic colorectal cancer

Allergy signs distribution agreement with Nycomed Canada for Pollinex Quattro

Relaxin shows promising results in phase II study in acute heart failure

Coartem receives FDA approval for malaria in the U.S.

DSMB recommends continuation of phase III Iluvien studies

KAI initiates third phase IIa KAI-1678 trial for neuropathic pain

Genentech voluntarily withdraws Raptiva from the U.S. market

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...